Dimesna free acid
Based on 1 publication(s) in Google Scholar
Dimesna (BNP-7787) free acid, the disulfide form of Mesna (HY-13679), is a platinum-related toxicity protective agent. Dimesna free acid converts to Mesna, which in turn inactivates toxic platinum substances. Dimesna free acid does not interfere with the antitumor activity of platinum compounds. Dimesna free acid does not affect the antiproliferative effects of Cisplatin (HY-17394) or Carboplatin (HY-17393). Dimesna free acid counteracts Cisplatin-induced nephrotoxicity. Dimesna free acid exerts selective protective effects on the kidneys. Dimesna free acid can be used in studies related to ovarian cancer and Cisplatin-induced nephrotoxicity.
For research use only. We do not sell to patients.
- CAS No.: 45127-11-5
- Formula: C4H10O6S4
- Molecular Weight:282.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dimesna free acid
More
Biological Activity
Dimesna (0-5.0 mmol/L; 1-24 h) free acid alone exerts no effect on total protein, thymidine incorporation or uridine incorporation in LLC-PK1 cells, and fails to protect LLC-PK1 cells from toxicity induced by ifosfamide, cyclophosphamide, 4-hydroperoxyifosfamide, chloroacetaldehyde or acrolein[1].
Dimesna (≥2.0×103 μM; 96 h) free acid does not reduce the antiproliferative effects of cisplatin or carboplatin on A2780 or OVCAR-3 ovarian cancer cells, and only inhibits the growth of these cells when exposed for 96 h at a concentration of ≥2.0×103 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LLC-PK1 renal tubular cells
-
Concentration:0-5.0 mmol/l (alone; co-incubated with ifosfamide/cyclophosphamide/4-OOH-ifosfamide/chloracetaldehyde/acrolein); 1.0-5.0 mmol/l (co-incubated with 4-OOH-cyclophosphamide)
-
Incubation Time:1-24 h (alone); 1 h pre-incubation + 23 h co-incubation (with cytostatic metabolites)
-
Result:Had no significant effect on total protein, thymidine incorporation, or uridine incorporation at all tested concentrations and times when used alone.
Moderately stimulated thymidine incorporation, but had no significant effect on total protein or uridine incorporation when co-incubated with 150 μmol/l ifosfamide.
Had no significant effect on total protein, thymidine incorporation, or uridine incorporation when co-incubated with 150 μmol/l cyclophosphamide.
Further reduced total protein and thymidine incorporation at 1.0, 3.0, 5.0 mmol/l, and further reduced uridine incorporation at 3.0, 5.0 mmol/l (P < 0.05) when co-incubated with 75 μmol/l 4-OOH-cyclophosphamide.
Failed to protect cells from toxicity induced by 150 μmol/l 4-OOH-ifosfamide, with total protein, thymidine incorporation, and uridine incorporation remaining strongly reduced.
Failed to protect cells from toxicity induced by 75 μmol/l chloracetaldehyde, with no statistically significant difference in total protein, thymidine incorporation, or uridine incorporation compared to chloracetaldehyde alone.
Failed to protect cells from toxicity induced by 100 μmol/l acrolein, with total protein, thymidine incorporation, and uridine incorporation remaining severely reduced.
Dimesna (BNP-7787) (1000 mg/kg; i.v.; bolus injection) free acid administered to tumour-bearing Fischer rats results in preferential accumulation of its metabolite mesna in the kidney, with kidney mesna AUC0-t 4.5-fold higher than plasma mesna AUC0-t, while maintaining low mesna levels in plasma and tumour tissue relative to mesna administration[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hsd: athymic nude-nu (female, 8-10 weeks old)[2]
-
Dosage:1000 mg/kg (pre-cisplatin 5 mg/kg); 1000 mg/kg (pre-cisplatin 8 mg/kg); 1000 mg/kg (with carboplatin 60 mg/kg); 1000 mg/kg (with carboplatin 90 mg/kg); 1000 mg/kg (monotherapy)
-
Administration:i.v.; weekly ×2 (pre-cisplatin 5 mg/kg); i.v.; every 2 weeks ×2 (pre-cisplatin 8 mg/kg); i.v.; twice per treatment cycle, weekly ×2 (with carboplatin 60 mg/kg); i.v.; twice per treatment cycle, weekly ×2 (with carboplatin 90 mg/kg); i.v.; weekly ×2 (monotherapy)
-
Result:Exhibited mean maximum weight loss of 6.6±6.1%, no toxic deaths, specific growth delay of 3.48, and mean relative tumour volume of 2.55±0.42 on day 31 when given 5 minutes before 5 mg/kg cisplatin, with no significant difference in tumour growth inhibition compared to cisplatin alone.
Exhibited mean maximum weight loss of 24.8±9.2%, no toxic deaths, specific growth delay of 6.34, and mean relative tumour volume of 0.39±0.08 on day 31 when given 5 minutes before 8 mg/kg cisplatin, with no significant difference in tumour growth inhibition compared to amifostine-pretreated cisplatin.
Exhibited mean maximum weight loss of 9.9±11.9%, no toxic deaths, specific growth delay of 4.72, and mean relative tumour volume of 0.50±0.14 on day 31 when given with 60 mg/kg carboplatin, which was significantly smaller than carboplatin alone (P<0.01).
Exhibited mean maximum weight loss of 11.4±3.1%, 2 out of 6 mice died from toxicity, specific growth delay of 8.44, and mean relative tumour volume of 0.17±0.03 on day 31 when given with 90 mg/kg carboplatin.
Exhibited mean maximum weight loss of 0.0±3.2%, no toxic deaths, specific growth delay of 0.22, and mean relative tumour volume of 29.28±4.38 on day 31 as monotherapy, with no tumour growth inhibition observed.
Chemical Information
-
CAS No. 45127-11-5
-
Molecular Weight 282.38
-
Formula C4H10O6S4
-
SMILES
O=S(O)(CCSSCCS(=O)(O)=O)=O
-
Synonyms
BNP-7787 free acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112
Purity & Documentation
References
[1]. Mohrmann M, et al. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Pediatr Nephrol. 1994;8(4):458-465. [Content Brief]
[2]. Boven E, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002;38(8):1148-1156. [Content Brief]
[3]. Verschraagen M, et al. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. Br J Cancer. 2004;90(8):1654-1659. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dimesna free acid Related Classifications
HY-B1022A Related Classifications
Powered by Bioz